Facts: Always important to stick to the facts
COMPANY: Based in Israel. NEWS RELEASE states, "We were pleased to see the encouraging immune response and are excited to pursue further testing to highlight the unique advantages of SPs as a technology, though we had hoped to be able to demonstrate higher levels of protection in our first challenge experiment. Its not uncommon to see such results at this early stage. We will work diligently with our international team of experts to further understand the data as COVID-19 is unfortunately going to be around for a long time. Whilst we had hoped to get into the clinic sooner, we believe that our technology could still be very relevant in the fight against COVID-19 and other infectious diseases, said David Goren, Vaxils Chairman and Chief Executive Officer.